Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation.
Rotow, Julia K
Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation. [electronic resource] - Clinical lung cancer 03 2019 - e137-e141 p. digital
Publication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't
1938-0690
10.1016/j.cllc.2018.11.003 doi
Adenocarcinoma--diagnosis
Antineoplastic Agents--therapeutic use
Crizotinib--therapeutic use
Exons--genetics
Female
Humans
Lung Neoplasms--diagnosis
Middle Aged
Mutation--genetics
Neoadjuvant Therapy
Prognosis
Protein Kinase Inhibitors--therapeutic use
Proto-Oncogene Proteins c-met--genetics
Remission Induction
Treatment Outcome
Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation. [electronic resource] - Clinical lung cancer 03 2019 - e137-e141 p. digital
Publication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't
1938-0690
10.1016/j.cllc.2018.11.003 doi
Adenocarcinoma--diagnosis
Antineoplastic Agents--therapeutic use
Crizotinib--therapeutic use
Exons--genetics
Female
Humans
Lung Neoplasms--diagnosis
Middle Aged
Mutation--genetics
Neoadjuvant Therapy
Prognosis
Protein Kinase Inhibitors--therapeutic use
Proto-Oncogene Proteins c-met--genetics
Remission Induction
Treatment Outcome